Colorectal Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 years or older.
- People who have been diagnosed with metastatic colorectal cancer (cancer of the bowel that has spread to other parts of the body) and whose treating doctor has decided that treatment with a medicine called fruquintinib is appropriate, in line with the current approved prescribing guidelines in Germany.
- People who have already received standard chemotherapy treatments, including specific drug combinations (fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies), as well as treatment targeting a process called blood vessel growth (anti-VEGF therapy), and — for those whose tumour has a specific genetic profile called RAS wild-type — treatment targeting a protein called EGFR (anti-EGFR therapy).
- People whose cancer got worse during, or who could not tolerate, treatment with either of two specific medicines: trifluridine/tipiracil or regorafenib (or both).
- People who meet any additional requirements listed in the current approved prescribing guidelines for fruquintinib (confirm with trial site).
- People who have signed a written consent form agreeing to take part in the trial.
Who may not be able to join:
- People who took part in another interventional clinical trial (a trial involving a medical treatment or procedure) within the 30 days before enrolling in this trial or before starting fruquintinib, whichever happens first.
- People who have medical reasons that make fruquintinib unsuitable for them, as listed in the current approved prescribing guidelines (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Professor Dr. med. Sebastian Stintzing, Charité Campus Mitte Medizinische Klinik Hämatologie/Onkologie und Tumorimmunologie
Phone: +49 761 152420
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Real-world disease control rate (RW DCR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.